ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
iShares Neuroscience and Healthcare ETF
37.31
-0.1119
-0.30%
成交量：
1,718
成交額：
6.46萬
市值：
746.29萬
市盈率：
- -
高：
37.75
開：
37.31
低：
37.31
收：
37.43
52周最高：
43.01
52周最低：
25.42
股本：
20.00萬
流通股本：
20.00萬
量比：
1.12
換手率：
0.86%
股息：
0.32
股息率：
0.86%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
市場消息：Spotify 首席執行官埃克表示，Neko Health 正與腦機接口公司 Neuralink 開展合作。
智通财经
·
08/23
Scholar Rock撤回了針對肌肉無力藥物的歐洲申報，計劃重新提交
路透中文
·
08/21
福瑞醫科(300049.SZ)：公司暫無腦機接口的研究
中金财经
·
08/21
Scholar Rock控股公司獲日本PMDA認可，無需補充臨床研究；計劃2026年底提交Apitegromab上市申請
美股速递
·
08/21
Scholar Rock Holding公司撤回歐洲上市申請，計劃以替代灌裝生產線重新提交
美股速递
·
08/21
Scholar Rock Holding Corp：蓄勢待發，靜候FDA批准，Apitegromab擬於2026年9月30日PDUFA日期登陸美國市場
美股速递
·
08/21
深圳落地腦機接口數據知識產權登記
智通财经
·
08/21
佔國內近30%！閔行這裏憑什麼吸引企業和人才？
滚动播报
·
08/21
山西首例侵入式腦機接口植入術完成 截癱患者有望重塑運動功能
智通财经
·
08/20
光谷集中揭牌6個腦機接口科創平台
格隆汇
·
08/20
上海張江高新技術產業開發區發展「十五五」規劃：加速腦機接口技術從實驗室走向臨床應用、形成產品
智通财经
·
08/19
保險助力腦機接口走向臨床
经济日报
·
08/19
華中首例全侵入式腦機接口手術實施：55歲高位截癱女子可腦控輪椅
快科技
·
08/18
「從0到1」，江西如何搶灘未來產業？
江南都市报
·
08/18
AI驅動的超聲腦機接口公司思升科技完成數千萬元種子+輪融資
智通财经
·
08/18
超聲腦機接口公司思升科技獲數千萬元融資
智通财经
·
08/18
滾動市盈率相對較低的腦機接口概念股梳理
智通财经
·
08/18
9月10日起實施 浙江出台18條舉措，推進腦機接口領域發展
智通财经
·
08/14
美國研究綜述-愛彼迎、Five Below、Silgan Holdings
路透中文
·
08/13
美銀證券：中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價
新浪港股
·
08/13
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBRN/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":37.3143,"timestamp":1789416000000,"preClose":37.4262,"halted":0,"volume":1718,"delay":0,"changeRate":-0.0029898840918928062,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"盤前交易","change":-0.1119,"latestTime":"09-15 04:36:49 EDT","open":37.31,"high":37.745,"low":37.31,"amount":64609,"amplitude":0.011623,"askPrice":59.32,"askSize":100,"bidPrice":33.51,"bidSize":50,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":37.3143,"sharesOutstanding":150000,"nav":37.384466,"aum":7476893.2,"dividendRate":0.008603,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.5999,"preClose":37.3143,"latestTime":"16:10 EDT","volume":8,"amount":298.4058,"timestamp":1789416603823,"change":0.2856,"changeRate":0.007654,"amplitude":0},"volumeRatio":1.1163092482270598,"impliedVol":0.1627,"impliedVolPercentile":0.856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1163092482270598,"shares":200000,"dividePrice":0.321,"high":37.745,"amplitude":0.011623,"preClose":37.4262,"low":37.31,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":37.3143,"committee":-0.333333,"eps":0,"divideRate":0.008603,"volume":1718,"delay":0,"ttmEps":0,"open":37.31,"prevYearClose":32.3193,"prevWeekClose":37.4262,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":39.0596,"twentyDayClose":39.1355,"sixtyDayClose":35.5221},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661217889","title":"市場消息：Spotify 首席執行官埃克表示，Neko Health 正與腦機接口公司 Neuralink 開展合作。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217889","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661217889?lang=zh_tw&edition=fundamental","pubTime":"2026-08-23 09:50","pubTimestamp":1787449827,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1861215975.USD","LU2362541273.HKD","LU2362541513.USD","LU2250418816.HKD","LU2290526834.HKD","BK4571","LU2360106780.USD","LU0056508442.USD","LU2098885051.SGD","LU1303367103.USD","SPOG","BK4108","BK4585","LU1861220033.SGD","LU0786609619.USD","BK4548","LU1804176565.USD","SPOT","MNTL","LU1852331112.SGD","LU2265009873.SGD","BK4588","LU2360107168.USD","IBRN","LU1983260115.SGD","LU2362540622.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729986","title":"Scholar Rock撤回了針對肌肉無力藥物的歐洲申報，計劃重新提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729986","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729986?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 22:48","pubTimestamp":1787323684,"startTime":"0","endTime":"0","summary":"Scholar Rock撤回了针对肌肉无力药物的欧洲申报，计划重新提交路透8月21日-Scholar Rock公司SRRK.O周五表示，已撤回其针对一种实验性脊髓性肌萎缩症药物的欧洲上市申请，并计划在诺和诺德旗下工厂出现问题后，选择其他生产基地重新提交申请NOVOb.CO。Scholar Rock表示，公司已将其美国FDA申请中涉及的印第安纳州生产基地移除，并继续预期监管机构将在9月30日的目标行动日期前作出批准决定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL4T44I0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THNR","IBRN","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293498","title":"福瑞醫科(300049.SZ)：公司暫無腦機接口的研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293498","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661293498?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:17","pubTimestamp":1787318223,"startTime":"0","endTime":"0","summary":"格隆汇8月21日丨福瑞医科(300049.SZ)在投资者互动平台表示，公司暂无脑机接口的研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260821/32343226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IBRN","BK0114","BK0096","BK0028","300049","BK0113","MNTL","BK0251","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132368667","title":"Scholar Rock控股公司獲日本PMDA認可，無需補充臨床研究；計劃2026年底提交Apitegromab上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1132368667","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132368667?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:12","pubTimestamp":1787317946,"startTime":"0","endTime":"0","summary":"Scholar Rock控股公司迎来重大利好——日本药品和医疗器械管理局（PMDA）已明确表态，认为无需再进行额外的临床研究。这一进展为该公司旗下在研药物Apitegromab的日本上市之路扫清了关键障碍。据此，Scholar Rock计划于2026年底前正式向PMDA提交该药物的上市许可申请（JNDA）。此举标志着公司在全球战略布局中迈出了坚实一步，尤其在亚太核心市场的推进节奏上，展现出明确的执行力与前瞻性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162355391","title":"Scholar Rock Holding公司撤回歐洲上市申請，計劃以替代灌裝生產線重新提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1162355391","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162355391?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:12","pubTimestamp":1787317928,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation宣布，已主动撤回其药物Apitegromab在欧洲的上市许可申请。这一决定并非基于任何安全性或有效性方面的顾虑，而是源于生产环节中的具体问题。公司表示，将转而采用另一条灌装生产线，并计划在调整完成后重新提交申请。Scholar Rock管理层在声明中表达了对项目前景的信心，并承诺将与欧洲监管机构保持密切沟通，以确保后续流程高效推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THNR","IBRN","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158808120","title":"Scholar Rock Holding Corp：蓄勢待發，靜候FDA批准，Apitegromab擬於2026年9月30日PDUFA日期登陸美國市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1158808120","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158808120?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:10","pubTimestamp":1787317810,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corp已经做好全面准备，一旦获得美国食品药品监督管理局的批准，其药物Apitegromab即刻启动在美国市场的上市进程。这一关键节点锁定在2026年9月30日的《处方药使用者付费法案》目标日期。公司上下正厉兵秣马，为这一刻的到来铺平道路。届时，Apitegromab将迅速投放市场，惠及广大患者。这一战略部署彰显了公司对产品获批的坚定信心，也体现了其对市场需求的敏锐把握。随着PDUFA日期的临近，一场精心筹备的市场登陆战即将拉开帷幕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260001","title":"深圳落地腦機接口數據知識產權登記","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260001","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 20:19","pubTimestamp":1787314755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","PATN","IBRN","ITAN","NXTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661252356","title":"佔國內近30%！閔行這裏憑什麼吸引企業和人才？","url":"https://stock-news.laohu8.com/highlight/detail?id=2661252356","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661252356?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 13:30","pubTimestamp":1787290200,"startTime":"0","endTime":"0","summary":"依托新虹桥国际医学中心的优质临床禀赋，闵行全域脑机接口创新企业达到60余家，在国内脑机接口产业领域占比近30%，占全市比例六成以上,闵行没有止步于“建载体、引企业”的传统产业培育路径，而是以机制创新破局，探索形成“医-产-研-企”深度协同的产业培育新范式，推动创新资源从简单叠加走向深度融合，让全国首个脑机接口未来产业集聚区持续释放生长动能。闵行坚持“引育并举、生态留才”，让人才与产业同成长、共发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-21/doc-inipaent8145486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660470622","title":"山西首例侵入式腦機接口植入術完成 截癱患者有望重塑運動功能","url":"https://stock-news.laohu8.com/highlight/detail?id=2660470622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660470622?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 11:17","pubTimestamp":1787195870,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660717854","title":"光谷集中揭牌6個腦機接口科創平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2660717854","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660717854?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 08:35","pubTimestamp":1787186113,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNTL","IBRN","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660341989","title":"上海張江高新技術產業開發區發展「十五五」規劃：加速腦機接口技術從實驗室走向臨床應用、形成產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2660341989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660341989?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 10:39","pubTimestamp":1787107148,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490552","title":"保險助力腦機接口走向臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490552","media":"经济日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490552?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 06:00","pubTimestamp":1787090442,"startTime":"0","endTime":"0","summary":"随着脑机接口技术加速从实验室走向临床，配套的风险保障也在同步跟进。近期，保险行业聚焦临床试验、手术意外、患者保障等关键环节创新保险产品，既减轻患者接受前沿创新诊疗的负担和顾虑，也为医疗机构开展高精尖脑机临床手术提供风险托底，减少前沿技术临床推广阻碍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193844985910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193844985910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660457014","title":"華中首例全侵入式腦機接口手術實施：55歲高位截癱女子可腦控輪椅","url":"https://stock-news.laohu8.com/highlight/detail?id=2660457014","media":"快科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660457014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 14:06","pubTimestamp":1787033215,"startTime":"0","endTime":"0","summary":"快科技8月18日消息，华中科技大学附属同济医院近日完成华中地区首例全侵入式脑机接口手术。这名患者两年前遭遇意外，脊髓受损造成高位截瘫。此次植入的产品是国内首款高通量单神经元级脑机接口产品，也是目前全球创伤最小的全侵入式脑控产品，已获国家药监局创新医疗器械认定。这次手术落地，也代表华中地区已经集齐全侵入、半侵入、非侵入三类脑机接口临床能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vfVlkO4Yyr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456723","title":"「從0到1」，江西如何搶灘未來產業？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456723","media":"江南都市报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456723?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:43","pubTimestamp":1787020980,"startTime":"0","endTime":"0","summary":"一周内三场高规格活动，释放的信号再明确不过：江西的未来产业已从战略谋划全面推向实战攻坚。把短板转化为制度创新的突破口，正是江西布局未来产业最核心的逻辑。全省“十五五”规划纲要对“前瞻布局未来产业”作出专项部署，提出“实施未来产业发展示范工程”。03三类制度创新，实现“从0到1”制度创新如何从文件落到地面？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-18/doc-inintatv7378765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IQM","WDRN","IBRN","PBOT","RTOO","MNTL","ROBT","HDRO","UBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456362","title":"AI驅動的超聲腦機接口公司思升科技完成數千萬元種子+輪融資","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456362?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:14","pubTimestamp":1787019265,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","VTHR","MNTL","ARTY","CHAT","AGIX","QTOC","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660345525","title":"超聲腦機接口公司思升科技獲數千萬元融資","url":"https://stock-news.laohu8.com/highlight/detail?id=2660345525","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660345525?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 09:56","pubTimestamp":1787018197,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660126430","title":"滾動市盈率相對較低的腦機接口概念股梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2660126430","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660126430?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 07:25","pubTimestamp":1787009104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659113553","title":"9月10日起實施 浙江出台18條舉措，推進腦機接口領域發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2659113553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659113553?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 14:16","pubTimestamp":1786688167,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713954","title":"美國研究綜述-愛彼迎、Five Below、Silgan Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713954","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659713954?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 14:50","pubTimestamp":1786603808,"startTime":"0","endTime":"0","summary":"美国研究综述-爱彼迎、Five Below、Silgan Holdings路透8月13日-周四，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括爱彼迎、Five Below和Silgan Holdings。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4S44A0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIVE","ELIS","FLY","CAH","MSGE","ABNB","UNCY","ANRO","Z","CURE","MNSH","NURE","RHP","SLGN","PARK","CYTK","MNPR","SPHR","ACM","EAT","SRRK","LLY","LOW","YELP","DUOL","AMTM","PTCT","ZG","INSW","CSCO","KURA","FLYT","IBRN","TRIP","PAYX","LLII","COHR","OSCR","HP","ALGM","MTSI","TRAX","ARMK","BOAT","LQDA","INO","OZEM","OII","OI","AMRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美銀證券：中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","IBRN","APXH","02359","603259","BMED","CXO","BBC","SURI","WX","MEDI","XBIX","IDNA","LFSC","PSIL","PSCH","SMCO","FHLC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}